Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
复制标题
DOI：
10.1111/ajad.13084
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Stowe ZN
中科院分区：
文献类型：
--
作者：
Ray-Griffith S;Tharp E;Coker JL;Catlin D;Knight B;Stowe ZN
与阿片类药物使用障碍（OUD）孕妇的阿片类药物使用障碍（mod）治疗保留相关的因素在很大程度上是未知的。本研究试图描述与产后治疗保留相关的因素。回顾性分析2014 - 2017年丁丙诺啡治疗妊娠期OUD患者的资料。如果妇女在产后10-14周内参加了预约，则被分配到治疗保留组。其他人被分配到辍学组。采用双变量分析对两组进行比较，包括社会人口学变量、产科和新生儿结局、临床和主观阿片类药物戒断症状、丁丙诺啡剂量、尿药物毒理学（UDT）结果和其他因素。64例孕妇接受治疗至分娩，其中47例（73.1%）在产后12周仍在接受治疗。退出治疗组分娩时丁丙诺啡剂量较低，苯二氮卓类药物UDT阳性百分比较高，妊娠晚期苯二氮卓类药物UDT阳性数量较高。母乳喂养率在治疗保留组较高。未来需要对产后治疗保留的相关变量进行研究，以提供围产期mod的指导方针，并优化母婴健康。这项研究支持了先前的建议，即需要积极治疗OUD孕妇的戒断症状，以最大限度地保持治疗效果。这是首次发现母乳喂养与产后治疗保留有关的研究；然而，怀孕期间苯二氮卓类药物的使用增加与产后退出治疗有关。
Factors associated with medication for opioid use disorder (MOUD) treatment retention among pregnant women with opioid use disorder (OUD) are largely unknown. This study sought to characterize factors associated with postpartum treatment retention. A retrospective chart review from 2014 to 2017 was conducted among women with OUD in pregnancy treated with buprenorphine. Women were assigned to the treatment retention group if they attended an appointment within 10–14 weeks postpartum. Others were assigned to the dropout group. The groups were compared using bivariate analysis for sociodemographic variables, obstetrical and neonatal outcomes, clinical and subjective opioid withdrawal symptoms, buprenorphine dosage, urine drug toxicology (UDT) results, and other factors. A total of 64 pregnancies received treatment until delivery, and 47 (73.1%) were retained in treatment by 12 weeks postpartum. The treatment dropout group had lower buprenorphine doses at delivery, higher percentage of benzodiazepine positive UDT, and number of UDT positive for benzodiazepine in the 3rd trimester. Breastfeeding rates were higher in the treatment retention group. Future research of variables related to postpartum treatment retention is needed to provide guidelines regarding MOUD during the perinatal period and to optimize maternal and fetal well-being. This study supports previous recommendations that aggressive treatment of withdrawal symptoms in pregnant women with OUD is needed to maximize treatment retention. This is the first study to find that breastfeeding was associated with postpartum treatment retention; while, increased use of benzodiazepines during pregnancy was associated with postpartum treatment dropout.
登录
查看更多内容
影响因子：
7.2
作者：
Reddy, Uma M.;Davis, Jonathan M.;Greene, Michael F.
通讯作者：
Greene, Michael F.
影响因子：
4.2
作者：
Coker, Jessica L.;Catlin, David;Stowe, Zachary N.
通讯作者：
Stowe, Zachary N.
影响因子：
3.9
作者：
O'Connor, Alane B.;Uhler, Brett;Knuppel, Kyle
通讯作者：
Knuppel, Kyle
影响因子：
4.2
作者：
Wilder, Christine;Lewis, Daniel;Winhusen, Theresa
通讯作者：
Winhusen, Theresa
在一项多站点试验中，与美沙酮相比，随机分配给丁丙诺啡/纳洛酮的患者的治疗保留率。
DOI：
10.1111/add.12333
发表时间：
2014-01
期刊：
Addiction (Abingdon, England)
影响因子：
--
作者：
Hser YI;Saxon AJ;Huang D;Hasson A;Thomas C;Hillhouse M;Jacobs P;Teruya C;McLaughlin P;Wiest K;Cohen A;Ling W
通讯作者：
Ling W